Figure 2. NGF immunohistochemistry; A) normal group; axon (a), myelin sheath (arrow) (3,3′-diaminobenzidine, 40×); B) cisplatin+saline group, decreased axon diameter and NGF expression, degenerated myelin sheath (3,3′-diaminobenzidine, 40×); C) cisplatin+vitamin C group, increased axon diameter and NGF expression (3,3′-diaminobenzidine, 40×); and D) improved myelin sheath (3,3′-diaminobenzidine, 100×).
